<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648192</url>
  </required_header>
  <id_info>
    <org_study_id>116681</org_study_id>
    <nct_id>NCT01648192</nct_id>
  </id_info>
  <brief_title>Phase I Study of GW856553 (Losmapimod)</brief_title>
  <official_title>A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Losmapimod in Healthy Japanese Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first study of losmapimod in Japanese subjects. This study will be a&#xD;
      single-center, single blind, phase I and two part study to characterize the safety,&#xD;
      tolerability, pharmacokinetic and pharmacodynamic profiles in healthy Japanese volunteers&#xD;
      (male and female of non-childbearing potential). Part1 will be a single dose, randomized,&#xD;
      three-period, placebo-controlled and dose escalation part. Each subject will participate in 3&#xD;
      dosing sessions, and receive, on separate days, three of four treatments of losmapimod 2.5,&#xD;
      7.5 and 20 mg, and the matching placebo in the fasted state after overnight fast (at least 10&#xD;
      hours). The design incorporates sufficient washout between treatments (at least 7 days after&#xD;
      the previous administration), and is an efficient design for the study objectives. Part 2&#xD;
      will be a fixed dose and placebo-controlled part. Each subject will participate in one dosing&#xD;
      session, and receive losmapimod 7.5 mg or the matching placebo twice daily in the fasted&#xD;
      state for 14 days. Only subjects will be blind to the sequence and dose studied. The study&#xD;
      will include the placebo treatment to allow a valid evaluation of adverse events attributable&#xD;
      to treatment versus those independent of treatment. Approximately 18 subjects in each part&#xD;
      will receive treatments of losmapimod and/or placebo in the design. The primary objective of&#xD;
      the study is to characterize the safety and tolerability of single doses and repeat doses of&#xD;
      losmapimod in healthy Japanese subjects. Serial pharmacokinetic samples will be collected and&#xD;
      safety assessments will be performed following each dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2012</start_date>
  <completion_date type="Actual">October 26, 2012</completion_date>
  <primary_completion_date type="Actual">October 26, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability (evaluated by the result of Clinical safety laboratory tests, vital signs and 12-lead ECG).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>up to 96h post dose.</time_frame>
    <description>Area under the concentration-time curve from pre-dose to last time of quantifiable concentration of losmapimod and GSK198602 (inactive metabolite) (Single dose only).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>up to 96h post dose.</time_frame>
    <description>Area under the concentration-time curve from time pre-dose extrapolated to infinite time of losmapimod and GSK198602 (Single dose only).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tau)</measure>
    <time_frame>up to 17 days post dose.</time_frame>
    <description>Area under the concentration-time curve over the dosing interval of losmapimod and GSK198602 (Repeat dose only).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Maximum observed concentration of losmapimod and GSK198602.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Time of occurrence of Cmax of losmapimod and GSK198602.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Terminal phase half-life of losmapimod and GSK198602</description>
  </primary_outcome>
  <primary_outcome>
    <measure>accumulation ratios</measure>
    <time_frame>up to 17 days post dose.</time_frame>
    <description>accumulation ratios of losmapimod and GSK198602 (Repeat dose only).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Change from baseline in hsCRP after the oral dose of losmapimod.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphorylated HSP27</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Change from baseline in phosphorylated HSP27 assayed following ex vivo stimulation of cells in wholeblood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCex</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Percentage of AUC(0-inf) obtained by extrapolation of losmapimod and GSK198602.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tlast</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Time of last quantifiable concentration of losmapimod and GSK198602.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Î»z</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Terminal phase rate constant of losmapimod and GSK198602.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Apparent clearance following oral dosing of losmapimod.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.</time_frame>
    <description>Apparent volume of distribution following oral dosing of losmapimod.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>up to 17 days post dose.</time_frame>
    <description>Area under the concentration-time curve from time pre-dose extrapolated to infinite time of losmapimod and GSK198602 (Repeat dose only).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losmapimod for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losmapimod for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losmapimod for single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losmapimod for repeat dose (14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losmapimod for single dose</intervention_name>
    <description>Film coated white tablet</description>
    <arm_group_label>2.5 mg</arm_group_label>
    <arm_group_label>20 mg</arm_group_label>
    <arm_group_label>7.5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losmapimod for repeat dose</intervention_name>
    <description>Film coated white tablet</description>
    <arm_group_label>7.5 mg BID</arm_group_label>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included only if&#xD;
             the Investigator and the GSK Medical Monitor agree that the finding is unlikely to&#xD;
             introduce additional risk factors and will not interfere with the study procedures.&#xD;
&#xD;
          -  Male or female between 20 and 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females.&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods. This criterion must be followed from the time of the first&#xD;
             dose of study medication until follow-up visit.&#xD;
&#xD;
          -  Body weight &gt;= 45 kg and BMI within the range 18.5 - 29.0 kg/m2 (inclusive).&#xD;
&#xD;
          -  Japanese defined as being born in Japan, having four ethnic Japanese grandparents,&#xD;
             holding a Japanese passport or identity papers and being able to speak Japanese.&#xD;
             Japanese subjects must not have lived outside of Japan for more than 10 years.&#xD;
&#xD;
          -  ALT, alkaline phosphatase and bilirubin &lt;= 1.5xULN (isolated bilirubin &gt;1.5xULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Single QTc, QTcB or QTcF &lt; 450 msec.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: an&#xD;
             average weekly intake of greater than 21 units for men and 14 for women or an average&#xD;
             daily intake of greater than 3 units. One unit is equivalent to a 285 mL glass of full&#xD;
             strength beer or 425 mL schooner of light beer or 1 (30 mL) measure of spirits or 1&#xD;
             glass (100 mL) of wine (NHMRC Guidelines [NHMRC, 2009])&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and GSK Medical Monitor the medication will not interfere with the study&#xD;
             procedures or compromise subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive urine hCG test at screening or prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History or regular use of tobacco- or nicotine-containing products within 6 months&#xD;
             prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116681</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116681</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116681</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116681</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116681</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116681</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116681</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

